Toni Choueiri, MD, Dana Farber Cancer Institute, Boston, MA, shares the results of cohort 1 of the Phase II LITESPARK-003 (NCT03634540) trial investigating belzutifan plus cabozantinib as first-line treatment of advanced renal cell carcinoma (RCC). The primary end point was confirmed objective response rate (ORR) and secondary end points were duration of response (DOR), progression-free survival (PFS), overall-survival (OS), and safety. ORR was 57%, median DOR was 28.6 months and median PFS was 30.3 months, with a manageable safety profile. Median OS was not reached.This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть